Cardiff Oncology Inc. (CRDF) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Cardiff Oncology Inc. (NASDAQ: CRDF) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.91 (+1.60% 1D, market cap $70.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CRDF ranks #509 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRDF carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GRML (Greenland Mines Ltd.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M) and CGTX (Cognition Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M). Among the 5-stock peer group, CRDF leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).
Per CRDF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001213037), Cardiff Oncology Inc. generated $593.0K in revenue (-13.2% YoY), -$45.9K in net income, and -$38.0M in free cash flow against $61.9M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 38.9 (NEUTRAL RANGE)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CRDF currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.08) and Max Pain ($0.96) forces dealer call-delta covering toward $3.48.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Cardiff Oncology Inc. (CRDF) advanced +1.60% to $0.91, trading at 6% of its 52-week range ($0.76 – $3.31). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Seasoned oncology executive brings extensive clinical development expertise and a track record of advancing innovative cancer therapiesSAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a
SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S. Food
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -13.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRDF today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRDF. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Cardiff Oncology Inc. (CRDF) ranks #509 by composite RQD confidence (41/100, grade D-) and #705 by equity capitalization ($70.9M). Within this direct 5-issuer industry benchmark cohort, CRDF leads on earnings valuation at N/A trailing P/E, while CSBR leads on capital efficiency and profitability with -26.9% ROIC and 48.0% gross margin. CGTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with CRDF at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRDF
ACTIVE
Cardiff Oncology Inc. | D- | 41/100 | — | — | -35.0% | +1.60% | $70.9M | Benchmark Subject |
| GRML Greenland Mines Ltd. | E | 32/100 | — | — | -35.0% | -5.69% | $70.3M | /grml-vs-crdf → |
| CGTX Cognition Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | -1.28% | $70.3M | /cgtx-vs-crdf → |
| NMRA Neumora Therapeutics Inc. | D- | 42/100 | — | — | -35.0% | -1.22% | $73.0M | /nmra-vs-crdf → |
| CSBR Champions Oncology Inc. | E | 22/100 | — | 48.0% | -26.9% | -2.24% | $66.9M | /csbr-vs-crdf → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cardiff Oncology Inc. (CRDF) reported GAAP revenue of $593.0K (-13.2% vs. FY2024 revenue of $683.0K , and +21.5% cumulative change since FY2023) , GAAP net income of -$45.9K, operating cash flow of -$37.9M, and free cash flow of -$38.0M (-0.5% YoY). On the balance sheet, CRDF closed FY2025 with $61.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $593.0K | -$45.9K | -$37.9M | -$38.0M | $61.9M | — |
| FY2024 (FY) | 2024-12-31 | $683.0K | -$45.4K | -$37.7M | -$37.8M | $97.2M | — |
| FY2023 (FY) | 2023-12-31 | $488.0K | -$41.4K | -$30.9M | -$30.9M | — | — |
As of 2026-11-02, Cardiff Oncology Inc. (NASDAQ: CRDF) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.91 (+1.60% 1D, market cap $70.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CRDF ranks #509 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRDF carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GRML (Greenland Mines Ltd.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M) and CGTX (Cognition Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M). Among the 5-stock peer group, CRDF leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).
Per CRDF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001213037), Cardiff Oncology Inc. generated $593.0K in revenue (-13.2% YoY), -$45.9K in net income, and -$38.0M in free cash flow against $61.9M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CRDF last traded at $0.91 (+1.60% on volume of 124,375 shares), positioning the stock -15.74% below its 50-day simple moving average ($1.08) and -36.81% below its 200-day simple moving average ($1.44). Across its 52-week range of $0.76 to $3.31, CRDF sits at the 5.9% percentile with a 14-day RSI of 38.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.02).
Why CRDF Stock advanced +1.60% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).